P067 impact of mirikizumab treatment on health-related quality of life in patients with ulcerative colitis: a phase 2 study analysis using the sf-36 v2 standard

Mirikizumab (LY3074828) is a humanized monoclonal antibody directed against the p19 subunit of IL-23, and had demonstrated efficacy in psoriasis, ulcerative colitis (UC), and Crohn ’s disease. The effect of miri on health-related quality of life (HRQoL) as measured by the 36-Item Short Form Health Survey v2 Standard (SF-36) was examined in a Phase 2, multicenter, randomized, parallel-arm, double-blind placebo (PBO)-controlled trial (NCT02891226) in patients with moderate to severely active UC.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Controlled Clinical Trials in Humans Source Type: research